Your browser doesn't support javascript.
loading
Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM): A Study from the ClinGen Cardiomyopathy Variant Curation Expert Panel.
Morales, Ana; Ing, Alexander; Antolik, Christian; Austin-Tse, Christina; Baudhuin, Linnea M; Bronicki, Lucas; Cirino, Allison; Hawley, Megan H; Fietz, Michael; Garcia, John; Ho, Carolyn; Ingles, Jodie; Jarinova, Olga; Johnston, Tami; Kelly, Melissa A; Kurtz, C Lisa; Lebo, Matt; Macaya, Daniela; Mahanta, Lisa; Maleszewski, Joseph; Manrai, Arjun K; Murray, Mitzi; Richard, Gabriele; Semsarian, Chris; Thomson, Kate L; Winder, Tom; Ware, James S; Hershberger, Ray E; Funke, Birgit H; Vatta, Matteo.
Afiliação
  • Morales A; Division of Human Genetics, The Ohio State University, Columbus, Ohio; Invitae Corp., San Francisco, California. Electronic address: ana.morales@invitae.com.
  • Ing A; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts.
  • Antolik C; Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California.
  • Austin-Tse C; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
  • Baudhuin LM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Bronicki L; Department of Genetics, CHEO, Ottawa, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Cirino A; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
  • Hawley MH; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts.
  • Fietz M; PathWest Laboratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; Illumina Inc., Scoresby, Victoria, Australia.
  • Garcia J; Invitae Corp., San Francisco, California.
  • Ho C; Cardiovascular Division, Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Ingles J; Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.
  • Jarinova O; Department of Genetics, CHEO, Ottawa, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Johnston T; Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California.
  • Kelly MA; Geisinger, Danville, Pennsylvania.
  • Kurtz CL; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.
  • Lebo M; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts; Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Macaya D; GeneDx, Inc, Gaithersburg, Maryland.
  • Mahanta L; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts.
  • Maleszewski J; Harvard Medical School, Boston, Massachusetts; Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
  • Manrai AK; Computational Health Informatics Program, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Murray M; GeneDx, Inc, Gaithersburg, Maryland.
  • Richard G; GeneDx, Inc, Gaithersburg, Maryland.
  • Semsarian C; Cardiovascular Division, Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Thomson KL; Oxford Medical Genetics Laboratories, Churchill Hospital, Oxford, United Kingdom.
  • Winder T; Invitae Corp., San Francisco, California.
  • Ware JS; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Cardiovascular Research Centre, Royal Brompton and Harefield NHS Foundation Trust, London, London, United Kingdom; MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
  • Hershberger RE; Division of Human Genetics, The Ohio State University, Columbus, Ohio; Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio.
  • Funke BH; Laboratory for Molecular Medicine, Partners HealthCare, Boston, Massachusetts; Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Vatta M; Invitae Corp., San Francisco, California; Departments of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
J Mol Diagn ; 23(5): 589-598, 2021 05.
Article em En | MEDLINE | ID: mdl-33631351
ABSTRACT
Diagnostic laboratories gather phenotypic data through requisition forms, but there is no consensus as to which data are essential for variant interpretation. The ClinGen Cardiomyopathy Variant Curation Expert Panel defined a phenotypic data set for hypertrophic cardiomyopathy (HCM) variant interpretation, with the goal of standardizing requisition forms. Phenotypic data elements listed on requisition forms from nine leading cardiomyopathy testing laboratories were compiled to assess divergence in data collection. A pilot of 50 HCM cases was implemented to determine the feasibility of harmonizing data collection. Laboratory directors were surveyed to gauge potential for adoption of a minimal data set. Wide divergence was observed in the phenotypic data fields in requisition forms. The 50-case pilot showed that although demographics and assertion of a clinical diagnosis of HCM had 86% to 98% completion, specific phenotypic features, such as degree of left ventricular hypertrophy, ejection fraction, and suspected syndromic disease, were completed only 24% to 44% of the time. Nine data elements were deemed essential for variant classification by the expert panel. Participating laboratories unanimously expressed a willingness to adopt these data elements in their requisition forms. This study demonstrates the value of comparing and sharing best practices through an expert group, such as the ClinGen Program, to enhance variant interpretation, providing a foundation for leveraging cumulative case-level data in public databases and ultimately improving patient care.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Cardiomiopatia Hipertrófica / Genoma Humano / Testes Genéticos / Genômica / Bases de Dados Genéticas Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Mol Diagn Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Cardiomiopatia Hipertrófica / Genoma Humano / Testes Genéticos / Genômica / Bases de Dados Genéticas Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Mol Diagn Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA